Almost 20 years ago, NF-κB was described as an essential modulator of BCR-ABL signaling in Chronic Myeloid Leukemia and Philadelphia-positive Acute Lymphoblastic Leukemia. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.